BioCentury
ARTICLE | Clinical News

DNA completes Phase III Avastin enrollment

December 7, 2001 8:00 AM UTC

Genentech (DNA) said it completed enrollment of 400 metastatic breast cancer patients in a Phase III trial of its Avastin in combination with Xeloda compared to Xeloda alone. Avastin, a monoclonal ant...